FRA:0DX (China)
Â
Ordinary Shares - Class H
€
7.15
-0.25 (-3.38%)
Aug 24
Business Description
Nanjing Leads Biolabs Co Ltd
NAICS : 541714
SIC : 2834
ISIN : CNE1000070H8
Share Class Description:
FRA:0DX: Ordinary Shares - Class HTotal Employee Number:
244Compare
Compare
Traded in other countries / regions
09887.Hong Kong0DX.Germany IPO Date
2026-02-02Description
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.52 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | -1.69 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 15.86 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y Total Revenue Growth Rate Estimate | 62.05 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.48 | |||||
9-Day RSI | 51.38 | |||||
14-Day RSI | 54.38 | |||||
3-1 Month Momentum % | -2.21 | |||||
6-1 Month Momentum % | -1.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.37 | |||||
Quick Ratio | 3.25 | |||||
Cash Ratio | 3.08 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -107.91 | |||||
Net Margin % | -118.28 | |||||
EBITDA Margin % | -93.53 | |||||
FCF Margin % | -93 | |||||
OCF Margin % | -87.13 | |||||
ROE % | -38.68 | |||||
ROA % | -20.61 | |||||
ROIC % | -37.04 | |||||
ROC (Joel Greenblatt) % | -391.43 | |||||
ROCE % | -33.85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 66.37 | |||||
PB Ratio | 10.61 | |||||
Price-to-Tangible-Book | 10.67 | |||||
EV-to-EBIT | -59.33 | |||||
EV-to-Forward-EBIT | -50.72 | |||||
EV-to-EBITDA | -66.91 | |||||
EV-to-Revenue | 62.58 | |||||
EV-to-Forward-Revenue | 37.29 | |||||
EV-to-FCF | -67.3 | |||||
| Price-to-Net-Current-Asset-Value | 11.53 | |||||
| Price-to-Net-Cash | 13 | |||||
Earnings Yield (Greenblatt) % | -1.69 | |||||
FCF Yield % | -1.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nanjing Leads Biolabs Co Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 21.492 | ||
| EPS (TTM) (€) | -0.147 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 54.38 | ||
| 14-Day ATR (€) | 0.316808 | ||
| 20-Day SMA (€) | 6.7375 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 5.15 - 10.5 | ||
| Shares Outstanding (Mil) | 198.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nanjing Leads Biolabs Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nanjing Leads Biolabs Co Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nanjing Leads Biolabs Co Ltd Frequently Asked Questions
What is Nanjing Leads Biolabs Co Ltd(FRA:0DX)'s stock price today?
The current price of FRA:0DX is €7.15. The 52 week high of FRA:0DX is €10.50 and 52 week low is €5.15.
When is next earnings date of Nanjing Leads Biolabs Co Ltd(FRA:0DX)?
The next earnings date of Nanjing Leads Biolabs Co Ltd(FRA:0DX) is .
Does Nanjing Leads Biolabs Co Ltd(FRA:0DX) pay dividends? If so, how much?
Nanjing Leads Biolabs Co Ltd(FRA:0DX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Nanjing Leads Biolabs Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers